Form 4: MapLight Therapeutics Executive Receives Stock Grant
Insider Transaction (Form 4)
James Woodruff Lillie, Chief Scientific Officer of MapLight Therapeutics, Inc., reported multiple transactions in common stock on August 17, 2026.
Summary
- Grant/award: acquired 7,730 Voting Common Stock on August 17, 2026; holds 210,110 after (Direct).
- Grant/award: acquired 31,395 Employee Stock Option (right to buy) on August 17, 2026; holds 31,395 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
James Woodruff Lillie — Officer (Chief Scientific Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-17 | Grant/award | Voting Common Stock | 7,730 | — | — | 210,110 |
| 2026-08-17 | Grant/award | Employee Stock Option (right to buy) | 31,395 | — | — | 31,395 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-17 | Grant/award (7,730 shares) |
| 2026-08-17 | Grant/award (31,395 shares) |
Keywords
insider transaction, Form 4, MPLT, MapLight Therapeutics, Inc., neutral, James Woodruff Lillie
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.